« Previous PageNext Page »

Rybelsus (semaglutide) for Type 2 Diabetes

Rybelsus (semaglutide) for Type 2 Diabetes: What You Need to Know

In today’s evolving healthcare landscape, the quest for better solutions for chronic conditions never ceases. Type 2 diabetes, a predominant form of diabetes affecting millions globally, has seen significant strides in treatment modalities. One such breakthrough is Rybelsus (semaglutide). As with any new medication, potential users have queries about its procurement, especially from online avenues and international markets like India. Let’s unravel the answers.

Introducing Rybelsus (semaglutide)

Rybelsus stands out as an oral tablet form of the glucagon-like peptide-1 (GLP-1) receptor agonist, semaglutide. While injectable GLP-1 agonists have been available, Rybelsus marks a transformation in administration convenience as an oral drug, making diabetes management less daunting for many.

Accessibility and Prescription Norms

Like many specialized medications, Rybelsus typically requires a prescription, how to buy without prescription read here. This ensures that its intake is tailored to individual needs and is under medical supervision, considering potential side effects and interactions with other drugs.

Those considering Rybelsus should consult their endocrinologist or primary care physician to evaluate its suitability and discuss the dosage.

Venturing Online for Rybelsus

With the digital era in full swing, online pharmacies have become a popular source for many. However, a few considerations are vital:

  • Verification: Always source medications from verified online pharmacies with credible certifications.
  • Prescription Mandate: Reliable platforms often request a prescription before processing an order for regulated drugs.
  • Beware of Counterfeits: The risk of counterfeits is real. Ensure the chosen platform has robust checks in place to guarantee the authenticity of medicines.

Indian Pharmacies and Rybelsus

India, known as the pharmacy of the world, has gained traction for providing quality medications at competitive prices. If considering Indian pharmacies for Rybelsus:

  • Regulatory Standards: Ensure the pharmacy adheres to the Indian regulatory standards, ensuring the drug’s quality and authenticity.
  • Shipping and Customs: Be aware of international shipping charges and potential customs restrictions or fees when ordering from overseas.
  • Prescription Recognition: Some Indian pharmacies might still require a prescription, even if it’s from another country.

Final Thoughts

Rybelsus presents a promising avenue for those managing type 2 diabetes. However, sourcing the medication requires due diligence, whether procured domestically, online, or internationally. Prioritize health and safety by always discussing with healthcare professionals and ensuring authentic sourcing. This not only guarantees the best results from the medication but also secures peace of mind in the treatment journey.

Disability Reporting Prizes Awarded

Each year, the National Center on Disability and Journalism recognizes the best reporting on disability being done around the world. The 2022 winners, which include BuzzFeed News, the Los Angeles Times and NPR, among others, can be found here.  

Annual prizes are awarded in both professional and student categories. The Katherine Schneider Journalism Award for Excellence in Reporting on Disability honors professional journalists in both small media and large media categories. The Gary Corcoran Student Prize for Excellence in Reporting on Disability recognizes the work of college student journalists.

The Schneider and Corcoran prizes are the only journalism contests devoted exclusively to the coverage of people with disabilities and disability issues.

The 2023 contest will open for entries in May 2023.

 

NCDJ and The New York Times Renew Disability Reporting Fellowship

The National Center on Disability and Journalism is partnering for a third year with The New York Times on a fellowship to develop journalists with an expertise in coverage of disability issues.

Early career journalists are encouraged to apply for the one-year fellowship to cover disability issues and people with disabilities as part of the incoming New York Times Fellowship class.

The Disability Journalism Fellowship is designed to address the lack of coverage of disability issues in journalism. It will provide fellows with mentorship, a peer network and training on covering disabilities. The position is funded through the Ford Foundation’s philanthropic support.

Applications will be accepted through March 24.

For more information, see the full release.

NCDJ and The New York Times Renew Disability Reporting Fellowship

The New York Times and the National Center on Disability and Journalism
announced that they are, for the third year in a row, partnering on a fellowship to
develop journalists with an expertise in coverage of disability issues.

This program again will recruit an early career journalist to work at The Times for
one year as a member of the incoming New York Times Fellowship class. The
newsroom is prepared to hire another Disability Journalism Fellow in early 2024.
The Disability Journalism Fellowship is designed to address the lack of coverage
of disability issues in journalism. It will provide fellows with mentorship, a peer
network and training on covering disabilities. The position is funded through the
Ford Foundation’s philanthropic support.

The application for 2023 is now open.
The New York Times Fellowship is a one-year work program aimed at cultivating
and diversifying the next generation of journalists. Since 2019, it has trained
more than 120 participants in reporting, visual, audio and other
disciplines. Amanda Morris, the inaugural Disability Journalism Fellow, is now a
reporter covering the disability community for The Washington Post. Neelam
Bohra, the current Disability Journalism Fellow, will complete her fellowship in
May.

The National Center on Disability and Journalism is a service of the Walter
Cronkite School of Journalism and Mass Communication at Arizona State
University. For over a decade at Cronkite, the center has provided support and
training for journalists and other communications professionals with the goal of
improving media coverage of disability issues and people with disabilities.

Should the term “special education” be retired?

Julia Métraux writes about the use of the term “special education” in an article for the NCDJ. An independent reporter and graduate student at University of California-Berkeley Graduate School of Journalism, Métraux makes an appeal to education reporters to find alternatives, even if school officials continue to use the language, which, she says, reinforces the view that disabled kids’ needs are “special.” Read more